BridgeBio Pharma (FRA:2CL) Momentum Rank: 10 (As of Sep. 09, 2026) — 43% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:2CL BridgeBio Pharma Inc FRA:2CL
66 GF Score
Price €64.57
GF Value €132.43
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is BridgeBio Pharma Momentum Rank?

BridgeBio Pharma FRA:2CL +0.69% 66 Momentum Rank is 10 as of Sep. 09, 2026, which is 43% above its 10-year median of 7.00. GuruFocus rates FRA:2CL with a GF Score™ of 66/100 and a GF Value™ of €132.43 (Possible Value Trap). The stock has 6 warning signs investors should review.

BridgeBio Pharma has the Momentum Rank of 10.

Momentum Rank measures the strength and persistence of a stock's price movement over time, rated on a scale of 1 to 10.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

A higher score reflects strong price momentum and indicates greater potential for superior performance. Conversely, a lower score indicates that momentum is either too high or too low, and stocks tend to underperform.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

BridgeBio Pharma Momentum Rank Related Terms

FRA:2CL vs JAZZ, ASND, EXEL: Momentum Rank Comparison

For the Biotechnology subindustry, BridgeBio Pharma's Momentum Rank, along with its competitors' market caps and Momentum Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BridgeBio Pharma Momentum Rank vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BridgeBio Pharma's Momentum Rank distribution charts can be found below:

* The bar in red indicates where BridgeBio Pharma's Momentum Rank falls into.


FRA:2CL
66GF Score
BridgeBio Pharma Inc FRA:2CL
Momentum Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Momentum Rank →
What does a Momentum Rank of 10 mean?
BridgeBio Pharma (FRA:2CL) has a Momentum Rank of 10 as of Sep. 09, 2026. Momentum Rank is determined using the standardized momentum ratio, measuring the speed and velocity of price changes in a stock. View historical data on BridgeBio Pharma and its competitors. This is 43% above median its historical median of 7.00. Over the past decade, BridgeBio Pharma's Momentum Rank has ranged from 2.00 to 10.00.
Is BridgeBio Pharma's Momentum Rank too high?
BridgeBio Pharma's current Momentum Rank of 10 is 43% above median its 10-year median of 7.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 10.00. Overall, BridgeBio Pharma has a GF Score™ of 66/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BridgeBio Pharma's Momentum Rank compare to JAZZ and ASND?
BridgeBio Pharma's Momentum Rank of 10 can be compared against companies in the Biotechnology industry. Historically, BridgeBio Pharma's own Momentum Rank has ranged from 2.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Momentum Rank for a Biotechnology company?
A good Momentum Rank depends on the Biotechnology industry context. However, Momentum Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Momentum Rank mean?
A high Momentum Rank can signal that a stock is expensive relative to its fundamentals. Momentum Rank is determined using the standardized momentum ratio, measuring the speed and velocity of price changes in a stock. View historical data on BridgeBio Pharma and its competitors. BridgeBio Pharma's current Momentum Rank is 10, which is 43% above median its own 10-year median of 7.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BridgeBio Pharma stock overvalued right now?
Based on GuruFocus' analysis, BridgeBio Pharma (FRA:2CL) is currently considered Possible Value Trap. The stock's GF Value™ is €132.43, compared to a current price of €64.57 — trading 51.2% below its estimated fair value. The current Momentum Rank is 10, which is 43% above median its 10-year median of 7.00. BridgeBio Pharma's overall GF Score™ is 66/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Momentum Rank calculated?
Momentum Rank is calculated from a company's financial statements. For BridgeBio Pharma (FRA:2CL), the current Momentum Rank is 10 as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BridgeBio Pharma (FRA:2CL) Overvalued in 2026?

Based on GuruFocus' analysis, BridgeBio Pharma stock appears to be undervalued. The current stock price of €64.57 is trading 51.2% below its estimated GF Value™ of €132.43. GuruFocus considers BridgeBio Pharma to be Possible Value Trap.

Key valuation signals for FRA:2CL:

  • Momentum Rank: 10 (43% above median its 10-year median of 7.00)
  • GF Value™: €132.43 vs. price of €64.57 (51.2% below fair value)
  • GF Score™: 66/100 with 6 warning signs

No single metric tells the full story. See the FRA:2CL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BridgeBio Pharma Business Description

Other Exchanges BBIO:USA1BBIO:Italy
Address 3160 Porter Drive, Suite 250, Palo Alto, CA, USA, 94304
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
66GF Score

Get the complete analysis for FRA:2CL

Momentum Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€64.57
Price
€132.43
GF Value